Sign in

NCT05698212RecruitingPhase 2

Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers

Proof-of-Concept, Obs Study to Evaluate Accuracy of MetriDx Lab Developed Test (LDT) to Accurately Identify Endometriosis-specific Biological Markers Using Micro-fluidic Analysis of Cells Enabling Clinicians to Diagnose Endometriosis

Source: ClinicalTrials.gov · Last updated 26 Jan 2023 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This study is testing a way to diagnose endometriosis using a uterine tissue biopsy (similar to a pap smear) as opposed to undergoing laparoscopy surgery. The tissue is sent to lab for cellular analysis with a proprietary AI (artificial intelligence) technology.

Status (registry)
Recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
75 (estimated)
First submitted
29 Nov 2022
Start date
14 Sept 2022
Primary completion date
25 Mar 2023
Lead sponsor
Hera Biotech, Inc.
NCT number
NCT05698212

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 75
  • From 14 Sept 2022 to the primary completion date, 25 Mar 2023
  • 3 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Has received excision or ablation surgical procedure or treatment, such as gonadotropin-releasing hormone (GnRH), for endometriosis within the past 12 months.
  • Cohort 3: Prior diagnosis of endometriosis, or surgical note from prior laparoscopy that indicates endometriosis lesions were observed.
  • Is currently taking a blood thinner medication.
  • Undergoing fertility or hormone therapy treatments.
  • Has participated in any interventional clinical trial in the previous 90 days in which an investigational drug was administered.

Other illness

  • Surgical history of hysterectomy.
  • Diagnosed with HIV, AIDS, hepatitis A, B, or C, or has active malignancy.
  • Has a complicating condition that would pose a hazard to tissue handling.
  • History of reproductive cancer.
  • Has a condition that, in the opinion of the investigator, would confound tissue collection or analysis.
  • Has an active pelvic infection or other infections contra-indicated for laparoscopy.
  • Has a history of alcohol or illegal drug/substance abuse, or suspected alcohol or illegal drug/substance abuse in the past two years.

Age

  • Younger than 18 or 51 years or older.

Other

  • Has a BMI 40 or above.
  • Currently, pregnant, breast feeding, or has given birth in the last 6 months.
  • History or evidence of uterine fibroids.

Who the study is looking for

  • Able to understand and provide informed consent.
  • Natural born female of childbearing potential.
  • Age between 18 and 50, inclusive.
  • Not pregnant at Visit 0 (screening) or Visit 1 (day of procedure).
  • Free of systemic or pelvic disorder that, in the opinion of the investigator, may interfere with the tissue collection procedure, analysis of the tissue or increase the risk to subject.
  • Must not have received excision or ablation surgical procedure or treatment, such as gonadotropin-releasing hormone (GnRH), for endometriosis within the past 12 months.
  • For Cohort 1 and 2:
    • Suspected of having endometriosis, or previously diagnosed with endometriosis, and currently recommended for laparoscopic surgery by physician.
    • Must have laparoscopic surgery within 60 days after screening Visit 0 and any time after the endometrial biopsy is obtained on Visit 1 (including the same day), or a laparoscopy on record within the 12 months prior to Visit 0 for diagnosis only.
    • Surgical report from prior laparoscopy must indicate that endometriosis was not treated with surgical ablation or excision.
    • Subjects will be assigned to Cohort 1 or 2 based on diagnosis and staging results from laparoscopy.
  • Or for Cohort 3:
    • Not suspected of having endometriosis
    • no previous diagnosis or symptoms of endometriosis, who have had a laparoscopy for another reason, such as tubal ligation or other abdominal procedure, within the past 12 months prior to screening Visit 0,
    • or laparoscopy to be completed within 60 days after screening Visit 0 and any time after the endometrial biopsy is obtained on Visit 1 (including the same day).
    • Surgeon's report must have no supplemental observations of endometriosis lesions or diagnosis. Subjects will be assigned to Cohort 3.

Age in the registry: 18 years to 50 years · Sex: Female · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (3)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Corpus Christi Women's Center
Coordinator of this site? Confirm its status
Corpus ChristiUnited StatesRecruiting
University of Texas Physician's Women's Center--Memorial City
Coordinator of this site? Confirm its status
HoustonUnited StatesRecruiting
Valley OB-GYN Clinic, PC
Coordinator of this site? Confirm its status
SaginawUnited StatesNot yet recruiting

This page is information, not medical advice. Discuss any trial with your doctor.